Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789045 | 0.85 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL6331284 | 0.84 | ALDH1A1 (0.40) | ALDH1A1HPGDLMNAKDM4ECYP3A4 | |
| SCHEMBL28125752 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL806499 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL23087443 | 0.78 | KDM4E (0.40) | ALDH1A1HPGDLMNAKDM4EMAPT | |
| SCHEMBL7064960 | 0.77 | IDO1 (0.50) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL12804046 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL19776358 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAMEN1KMT2A | |
| SCHEMBL31553097 | 0.77 | HTR2A (0.35) | — | |
| SCHEMBL23218740 | 0.74 | KMT2A (0.42) | ALDH1A1HPGDKMT2AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3653613-B1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC (CN) | 2022-11-16 | — | — | EP | disclosed |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | BEBETTER MED INC. (CN) | 2022-04-19 | — | — | US | disclosed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | BEBETTER MED INC. (CN) | 2021-04-29 | — | — | US | disclosed |
| EP-3484894-B1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20120101124-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443111-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| US-7045545-B1 | Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists | ELI LILLY AND COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-6967201-B1 | for increasing activation of the 5-HT2C receptor in mammals; treatment of depression, obesity, bulimia, premenstrual syndrome, alcoholism, tobacco abuse, panic disorder | ELI LILLY AND COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1204654-B1 | BENZOFURYLPIPERAZINES: 5-HT2C SEROTONIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1149085-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000044737-A1 | AMINOALKYLBENZOFURANS AS SEROTONIN (5-HT(2C)) AGONISTS | ELI LILLY AND COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122761-A1 | 1,3-DI-SUBSTITUTED KETENE COMPOUND AND APPLICATION THEREOF | PPARA, FABP1, PPARG | ALDH1A1 1018/4885HPGD 1146/4885LMNA 2054/4885 |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | ALDH1A1 2558/4885HPGD 1301/4885LMNA 1182/4885 |
| US-20120101124-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | ALDH1A1 1772/4885HPGD 1322/4885LMNA 2987/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | ALDH1A1 2680/4885HPGD 1286/4885LMNA 1336/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | ALDH1A1 2558/4885HPGD 1301/4885LMNA 1182/4885 |
| US-11306102-B2 | 1,3-di-substituted ketene compound and application thereof | PPARA, FABP1, PPARG | ALDH1A1 1018/4885HPGD 1146/4885LMNA 2054/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | ALDH1A1 1173/4885HPGD 2309/4885LMNA 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.